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Background: Constitutive activation of STAT3 is associated with the progression of hepatocellular carcinoma (HCC), and
abrogation of STAT3 signaling is a potential target for HCC treatment.
Results: A novel azaspirane modulates the JAK-STAT pathway in HCC.
Conclusion: The lead compound induces apoptosis by down-regulating STAT3 signaling.
Significance:This investigation reports a novel inhibitor of the JAK-STATpathwaywith the potential to target various cancers.
Signal transducer and activator of transcription 3 (STAT3) is
a transcription factor that regulates genes involved in cell
growth, proliferation, and survival, and given its association
with many types of cancers, it has recently emerged as a prom-
ising target for therapy. In this work, we present the synthesis of
N-substituted azaspirane derivatives and their biological evalu-
ation against hepatocellular carcinoma (HCC) cells (IC50  7.3
M), thereby identifying 2-(1-(4-(2-cyanophenyl)1-benzyl-1H-
indol-3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5) unde-
cane (CIMO) as a potent inhibitor of the JAK-STAT pathway
with selectivity over normal LO2 cells (IC50> 100M). The lead
compound, CIMO, suppresses proliferation of HCC cells and
achieves this effect by reducing both constitutive and inducible
phosphorylation of JAK1, JAK2, and STAT3. Interestingly,
CIMO displayed inhibition of Tyr-705 phosphorylation, which
is required for nuclear translocation of STAT3, but it has no
effect on Ser-727 phosphorylation. CIMO accumulates cancer
cells in the sub-G1 phase and decreases STAT3 in the nucleus
and thereby causes down-regulation of genes regulated via
STAT3. Suppression of STAT3 phosphorylation by CIMO and
knockdown of STAT3 mRNA using siRNA transfection dis-
played a similar effect on the viability of HCC cells. Further-
more, CIMO significantly decreased the tumor development in
an orthotopic HCC mouse model through the modulation of
phospho-STAT3, Ki-67, and cleaved caspase-3 in tumor tissues.
Thus, CIMO represents a chemically novel and biologically in
vitro and in vivo validated compound, which targets the JAK-
STAT pathway as a potential cancer treatment.
Hepatocellular carcinoma (HCC)7 is a fatal liver cancer
affecting 600,000 people worldwide annually (1), and it ranks
third in terms of global cancer mortality (2). The development
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and progression ofHCC is largely associatedwith endemic hep-
atitis B or hepatitis C virus infection, alcoholic hepatitis, non-
alcoholic steatohepatitis, hemochromatosis, obesity, and con-
sumption of aflatoxin B1 (3–5). Surgical therapies, including
liver resection and liver transplantation, as well as non-surgical
therapies, such as embolization, systemic chemotherapy, and
radiation therapy, have exhibited the highest efficacies in the
treatment of the neoplasm (6), and as with many cancers,
the detection and treatment ofHCC in early stages can enhance
the prognosis.
Signal transducer and activator of transcription 3 (STAT3) is
an inducible transcription factor present in the cytoplasm of
most cell types, and it is involved in extracellular signal trans-
duction to the nucleus by cytokines of the IL-6 family and epi-
dermal and platelet-derived growth factors and hence governs
cell differentiation, proliferation, and survival and, in a tumor,
its proliferation, development, survival, angiogenesis, metasta-
sis, and evasion (7, 8). Activation of STAT3 is also known to
transmit various survival signals by promoting the expression
of genes involved in cell cycle progression (cyclin D1), angio-
genesis (VEGF and HIF-1), cell migration (MMP-2/9), and
immune evasion (RANTES (regulated on activation normal T
cell expressed and secreted)) and antiapoptotic genes (Bcl2,
Bcl-xL, and survivin) (9, 10). JAK1, JAK2, JAK3, and tyrosine
kinase 2 (TYK2) are the upstream kinases that phosphorylate
different STATproteins and are involved in different functions.
Structurally, the activation of Janus kinase (JAK) and c-Src
kinase leads to the phosphorylation of tyrosine 705 and
homodimerization of STAT3, followed by its nuclear translo-
cation to transcribe the target genes. Constitutive activation of
STAT3 is observed in more than 15 types of solid and hemato-
logical tumors, including hepatocellular carcinoma, leukemia,
lymphoma, prostate cancer, breast cancer, ovarian cancer, and
multiple myeloma (11). To summarize, the critical role of
STAT3 in progression of in particular hepatocellular carci-
noma renders it a unique target for cancer treatment.
Azaspirane-based compounds have been studied extensively
and have been shown to have very good antioncogenic activity
in various tumor models (12). We previously reported sugar
mimetic (2-(2,6-difluorophenyl)-5-(4-methoxyphenyl)-1-oxa-
3-azaspiro(5,5) undecane) as an antitumor agent, which pos-
sesses binding affinity to cytokines and various growth factors
(13). Many discoveries have revealed that azaspiranes are good
inhibitors of various classes of tyrosine kinases. Specifically,
small molecules, such as atiprimod, azaspirane, staurosporines,
and lestaurtinib, are some of the known azaspirane-based tyro-
sine kinase inhibitors (14–16). Atiprimod and azaspirane are
structurally related compounds that were shown to inhibit
JAK2/JAK3 in preclinical studies, thereby suppressing cell pro-
liferation, along with angiogenesis-activating caspases, to drive
cell death (17, 18). Furthermore, it has been reported that stau-
rosporines show strong JAK3 inhibition (19). Lestaurtinib is an
orally bioavailable JAK2 inhibitor that is in phase II clinical
trials for acute myeloid leukemia (20, 21). However, the devel-
opment of atiprimod has been stalled due to commercial rea-
sons. The synthesis of staurosporines or lestaurtinib is a com-
plex phenomenon because they are isolated from Streptomyces.
Hence, we evolved the new scaffold shown in Fig. 1A.
Inhibition of upstream tyrosine kinases, such as JAK2/3, by a
smallmolecule now results in a decline of STAT3-targeted gene
expression, thereby inhibiting various biological processes cru-
cial for cancer cell survival and invasion. In the currentwork, we
synthesized and evaluated the effect of N-substituted azaspirane
derivatives on the JAK-STAT3 pathway in hepatocellular carci-
nomacells and found2-(1-(4-(2-cyanophenyl)1-benzyl-1H-indol-
3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5) undecane
(CIMO) as a potent inhibitor of this pathway. CIMO enhances
cytotoxicity, depletes the nuclear pool of STAT3, and down-regu-
lates constitutively active and inducible upstream kinases
(STAT3) and expression of target genes in vitro and in vivo, as will
be described inmore detail below.
EXPERIMENTAL PROCEDURES
Reagents—Hoechst 33342, MTT, Tris, glycine, NaCl, SDS,
and BSA were purchased from Sigma-Aldrich. Dulbecco’s
modified Eagle’s medium (DMEM), FBS, and antibiotic/anti-
mycotic mixture were obtained from Invitrogen. Rabbit poly-
clonal antibodies to STAT3 and mouse monoclonal antibodies
against phospho-STAT3 (Tyr-705) and Bcl-2, Bcl-xL, cyclin
D1, survivin, Bak, Bid, PTP1B, SHPTP1, SHPTP2, pro-
caspase-3, and PARP were obtained from Santa Cruz Biotech-
nology, Inc. Antibodies to phospho-specific Src (Tyr-416), Src,
phospho-specific JAK1 (Tyr-1022/1023), JAK1, phosphospe-
cific JAK2 (Tyr-1007/1008), and JAK2 were purchased from
Cell Signaling Technology (Beverly, MA). Goat anti-rabbit-
HRP conjugate and goat anti-mouseHRPwere purchased from
Sigma-Aldrich. Nuclear extraction and DNA binding kits were
obtained from Active Motif (Carlsbad, CA). Bacteria-derived
recombinant human IL-6 was purchased from ProSpec-Tany-
TechnoGene Ltd. (Rehovot, Israel).
Chemistry; Synthesis of 1-(2-Amino)-1-(4-methoxyphenylethyl)
Cyclohexanol
We initially prepared the compound 1-(2-amino-1-(4-
methoxyphenyl)-ethyl)-cyclohexanolmonoacetate as described
earlier (22).
Synthesis of 5-(4-Methoxyphenyl)-1-oxa-3-aza-spiro-(5,5) Un-
decane—To a stirred solution of 1-(2-amino)-1-(4-methoxy-
phenylethyl)-cyclohexanol 3 (1 eq) in methanol (10 ml), we
added various aldehydes (1.2 eq) and anhydrous potassium car-
bonate (2.5 eq), and the reaction mixture was stirred at room
temperature for 4–5 h. After the completion of the reaction,
water was added and extracted with ethyl acetate (15 ml). The
combined organic layer was dried over anhydrous sodium sul-
fate. The crude solid was obtained upon evaporation of the
solvent under reduced pressure and recrystallized from hexane
and ethyl acetate to furnish crystalline solid.
Cell Lines—HCC cell lines HepG2 and PLC/PRF5 cells were
obtained from the American Type Culture Collection (Manas-
sas, VA). Huh7-Luc, Hep3B, and LO2 cells were kindly pro-
vided by Prof. Kam Man Hui (National Cancer Centre, Singa-
pore). All of the cells were cultured in DMEM containing 1
antibiotic-antimycotic solution with 10% FBS.
WesternBlotting—For detection of phosphoproteins, CIMO-
treatedwhole-cell extractswere lysed in lysis buffer (20mMTris
(pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton
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X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.4 mM
PMSF, and 4 mM NaVO4). Lysates were then spun at 14,000
rpm for 10 min to remove insoluble material and resolved on
SDS gel. After electrophoresis, the proteins were electrotrans-
ferred to a nitrocellulose membrane, blocked with 5% nonfat
milk, and probed with various antibodies (1:1000) overnight at
4 °C. The blotwaswashed, exposed toHRP-conjugated second-
ary antibodies for 1 h, and finally examined by chemilumines-
cence (ECL; GE Healthcare).
To detect STAT3-regulated proteins and PARP, cells (2 
106/ml) were treated with CIMO for the indicated times in the
respective figures. The cells were then washed, and protein was
extracted by incubation for 30 min on ice in 0.05 ml of buffer
containing 20 mM HEPES, pH 7.4, 2 mM EDTA, 250 mM NaCl,
0.1%Nonidet P-40, 2g/ml leupeptin, 2g/ml aprotinin, 1mM
PMSF, 0.5 g/ml benzamidine, 1 mM DTT, and 1 mM sodium
vanadate. The lysate was centrifuged, and the supernatant was
collected. Whole-cell extract protein (30 g) was resolved on
SDS-PAGE; electrotransferred onto a nitrocellulose mem-
brane; blotted with antibodies against survivin, Bcl-2, Bcl-xL,
cyclin D1, Bak, Bid, ICAM-1, procaspase-3, and PARP; and
then detected by chemiluminescence (ECL; GE Healthcare).
Immunocytochemistry for STAT3 Localization—HepG2 cells
were plated in chamber slides in DMEM containing 10% FBS
and allowed to adhere for 24 h. Following treatmentwithCIMO
for 6 h, the cells were fixedwith cold acetone for 10min,washed
with PBS, and blocked with 5% normal goat serum for 1 h. The
cells were then incubated with rabbit polyclonal anti-human
STAT3 antibody (dilution, 1:100). After overnight incubation,
the cells were washed and then incubated with goat anti-rabbit
IgG-Alexa 594 (1:100) for 1 h and counterstained for nuclei
with Hoechst (50 ng/ml) for 5 min. Stained cells were mounted
with mounting medium (Sigma-Aldrich) and analyzed under a
fluorescence microscope (DP 70, Olympus, Tokyo, Japan).
DNA Binding Assay—DNA binding was performed using a
STAT3 DNA binding TransAMTM ELISA kit (Active Motif,
Carlsbad, CA). Briefly, nuclear extracts (5 g) from CIMO-
treated cells were incubated in a 96-well plate coated with oli-
gonucleotide containing the STAT3-specific DNA probe.
Bound STAT3 was then detected by a specific primary anti-
body. An HRP-conjugated secondary antibody was subse-
quently applied to detect the bound primary antibody and pro-
vided the basis for colorimetric quantification. The enzymatic
product was measured at 450 nm with a microplate reader
(Tecan Systems, San Jose, CA). The specificity of this assay was
tested by the addition of wild-type or mutated STAT3 consen-
sus oligonucleotide in the competitive or mutated competitive
control wells before the addition of the nuclear extracts.
Transfectionwith STAT3 siRNAand STAT3-mediatedTran-
scription Activity—Human STAT3, small interfering RNA
(siRNA), and the 2-macroglobulin luciferase reporter con-
structs have been described previously (23). Briefly, 60–70%
confluent cells in a 6-well plate were transfected using FuGENE6
(Roche Applied Science) transfection reagent. A luciferase
assay was performed using the Dual-Luciferase assay kit (Pro-
mega Corp., Singapore), Transfections were carried out in trip-
licate using 1g of the appropriate2-macroglobulin luciferase
reporter plasmid and empty vector per transfection along with
0.2 g of Renilla expression plasmid as a control for transfec-
tion efficiency. Luciferase activities were assayed 48 h after
transfection using the Dual-Luciferase assay system (Promega)
as described previously (23).
MTT Assay—The antiproliferative effect of CIMO against
HepG2 cells was determined by theMTTdye uptakemethod as
described previously (24, 25). Briefly, the cells (2.5  104/ml)
were incubated in triplicate in a 96-well plate in the presence or
absence of different concentrations of CIMO in a final volume
of 0.2 ml for up to 72 h at 37 °C. Thereafter, 20 l of MTT
solution (5 mg/ml in PBS) was added to each well. After 2 h of
incubation at 37 °C, 0.1 ml of lysis buffer (20% SDS, 50%
dimethylformamide) was added; incubation was continued
overnight at 37 °C; and the optical density at 570 nm was mea-
sured by a Tecan plate reader.
Flow Cytometric Analysis—To determine the effect of CIMO
on the cell cycle, cells were treated with CIMO at the indicated
time points (Fig. 1B) up to 48 h. Thereafter, cells were washed,
fixed with 70% ethanol, and incubated for 30 min at 37 °C with
0.1% RNase A in PBS. Cells were then washed again, resus-
pended, and stained in PBS containing 25 g/ml propidium
iodide for 30min at room temperature. Cell distribution across
the cell cycle was analyzed with a Beckman Coulter flow
cytometer.
Migration Assay—An IBIDI culture insert (IBIDI GmbH)
with two reservoirs separated by a 500-m-thick wall created
by a culture insert in a 35-mm Petri dish was used. 70 l of
HepG2 cells (5  105 cells/ml) were added into the two reser-
voirs of the same insert and incubated at 37 °C. After 12 h, the
insert was gently removed, creating a gap of500m.The cells
were treated with 5 M CIMO for 8 h before being exposed to
100 ng/ml CXCL12 for 24 h. The width of the wound was mea-
sured at time zero and after 24 h of incubationwith andwithout
CIMO in the absence or presence of CXCL12. Graphs were
plotted against the percentage of migration distance the cells
moved before and after treatment, normalized to control, as
described previously (26).
Invasion Assay—The invasion assay was performed with
slight modifications in a method described previously (27). A
BD BiocoatTM MatrigelTM invasion chamber with 8-m pores
in the light-tight polyethylene terephthalate membrane and
was coated with a reconstituted basement membrane gel (BD
Biosciences). 2  105 cells were suspended in serum-free
DMEM and seeded into the Matrigel transwell chambers. The
cells were incubated with CIMO for 8 h. After incubation, the
outer surfaces of the transwell chambers were wiped with cot-
ton swabs, and the invading cells were fixed and stained with
crystal violet solution. The invading cells were then counted in
five randomly selected areas under microscopic observation.
Orthotopic Implantation of HCC in Nude Mice—100 l con-
taining 3  106 Huh 7-Luc cells were injected subcutaneously
in the right flank of nude mice. When the tumor volume
reached 1 cm3, the tumor was harvested, cut into 2-mm3
pieces, and then implanted orthotopically into the liver of nude
mice. A midline abdominal incision (3–5 cm) was made to
expose the whole liver, and the liver capsule was mechanically
injured with a needle. A single piece of human HCC tissue (2
mm3)was filled into the liver tissue (whichwas visible as awhite
ANovel Azaspirane That Disrupts the JAK-STAT Pathway
34298 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 49•DECEMBER 5, 2014
 at U
N
IV
 O
F N
EW
 O
RLEA
N
S on February 24, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
spot) with forceps, and the abdominal wall was closed. The skin
incisions were closed with wound clips. The development of
tumors was monitored by imaging and quantification of the
bioluminescence signals using the Xenogen IVIS system (Cali-
per Life Sciences).
In Vivo Experiments—All animal experiments were per-
formed according to protocols approved by the SingHealth
Institutional Animal Use and Care Committee. For drug effi-
cacy study, 8-week-old athymic nu/nu female mice (Biolasco,
Taiwan) were implanted with the Huh 7-Luc cells orthotopi-
cally as described above. When the bioluminescence signal
reached 106, mice were treated either with vehicle (1%DMSO),
2 mg/kg CIMO, or 10 mg/kg CIMO 5 days a week intraperito-
neally. Tumor development was monitored twice a week by
measuring the bioluminescence signals. Mice were euthanized
when the humane end-point criterion ismet byCO2 inhalation.
Primary liver tumor and lung tissues were excised, snap-frozen,
and stored at80 °C until further analysis.
Immunohistochemical Analysis of Tumor Samples—Solid
tumors from control and drug-treated groups were fixed with
10% phosphate-buffered formalin, processed, and embedded in
paraffin. The sections were cut to 5-m size and deparaffinized
in xylene, dehydrated in graded alcohol, and finally hydrated in
water. Antigen retrievalwas conducted by boiling the slide in 10
mM sodium citrate (pH 6.0) for 30min. Immunohistochemistry
was conducted following themanufacturer’s instructions (Dako
LSAB kit). Briefly, endogenous peroxidases were quenched with
3% hydrogen peroxide. Sections were incubated with primary
antibodies for 2 h as follows: anti-phospho-STAT3, anti-Ki-67
and anti-caspase-3 (each at a 1:100 dilution). The slides were
subsequently washed several times in TBS with 0.1% Tween 20
and were incubated with biotinylated linker for 45 min, pro-
vided in the LSAB kit, according to the manufacturer’s instruc-
tions. Immunoreactive species were detected using 3,3-
diaminobenzidine tetrahydrochloride as a substrate. The
sections were counterstained with Gill’s hematoxylin and
mounted under glass coverslips. Images were taken using an
Olympus BX51microscope (magnification, 40). Quantitative
analyses of immunohistochemistry images were performed by
visual scores between the control and treated images. In this
expression quantitation technique, each image is divided into
four parts, and each part is individually quantitated for the bio-
marker expression. A cell scored as positive refers to the pres-
ence of brown staining (peroxidase) in any part of the studied
tissue. A negative score refers to no staining or weak staining.
Statistical Analysis—An unpaired t test withWelch’s correc-
tion was used for statistical comparisons between groups; p 
0.05 was considered statistically significant (GraphPad Prism
version 5.0, GraphPad Software).
RESULTS
Chemistry
Synthesis and Characterization of Novel Azaspiranes—Mul-
ticomponent reactions are a powerful tool to generate the
libraries of bioactive compounds. Herein, we synthesized a new
set of azaspiranes by utilizing the multicomponent reaction
involving 1-[2-amino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol-
monoacetate, aryl/benzyl/hetaryl halides, and various alde-
hydes via single step condensation and nucleophilic substitu-
tion reactions in one step. The title compounds were prepared
and recrystallized from hexane and ethyl acetate to furnish
crystalline solids. The structures of new azaspiranes were
deduced based on IR, 1H NMR, 13C NMR, and LCMS spectro-
scopic analysis.
Pharmacology
CIMO Suppresses Proliferation of HCC Cells in a Dose- and
Time-dependent Manner—We first investigated the antiprolif-
erative activity of the novel azaspiranes onHepG2 cells using an
MTTassay. Among the tested compounds, CIMOwas found to
be the most effective with an IC50 of 7.3 M, compared with
other structurally related azaspiranes, with an IC50 ranging
from 9.8 to50 M. Additionally, CIMOwas tested on a panel
of six cell lines, including Hep3B, PLC/PRF5, AGS, DU145,
MDA MB231, and CAL27 cells. CIMO exhibited a substantial
decrease of viable cells in all six tested cell lines. However,
CIMO did not show a high cytotoxic effect on LO2 cells up to
72 h at 100M, thereby indicating that the CIMOdoes not have
a cytotoxic effect on this non-diseased cell line.
CIMO Causes Accumulation of HepG2 Cells in Sub-G1
Phase—In late apoptosis, activation of endonucleases leads to
fragmentation of genomic DNA into oligomers, thereby con-
tributing to a decrease in DNA content, which in turn leads to
the buildup of cells in sub-G1 phase. In order to evaluate the
effect of CIMO on cell cycle distribution of HepG2 cells, we
performed flow cytometric analysis. HepG2 cells were treated
with CIMO at different time intervals up to 48 h and analyzed
cell cycle distribution after propidium iodide staining. Interest-
ingly, CIMO increased the accumulation of the sub-G1 cell
population to 18.8, 38.7, 71, and 92.1% at 16, 24, 36, and 48 h,
respectively (Fig. 1B).
CIMOPotently Inhibits Constitutive STAT3 Phosphorylation
in HCC Cells—Azaspiranes are well known for their inhibitory
action against JAK-STAT pathway. Therefore, we further
tested the library of new azaspiranes toward the inhibition of
constitutive activation of STAT3 in HepG2 cells by Western
blotting via antibodies recognizing phospho-STAT3 (Tyr-705).
It was found that CIMOpotently inhibited the phosphorylation
of STAT3 comparedwith other structural analogues. As shown
in Fig. 2, A and C, levels of phospho-STAT3 were found to be
substantially down-regulated in a dose- and time-dependent
manner, with maximum inhibition identified at 20 M and 6 h.
At the same time, STAT3 protein expression remained
unchanged (Fig. 2, A and C, bottom). We observed that expo-
sure to AG490, a well known inhibitor of JAK2, decreased the
phosphorylation of STAT3 in a dose-dependent manner in
HepG2 cells with the maximum inhibition at 200 M for 6 h
(Fig. 2B) (28). However, CIMO showed a comparable effect
already at a 10-fold lower concentration and hence much
higher potency.
Effect of CIMO on STAT3 Phosphorylation Is Specific for
Tyr-705—Given that STAT3 can undergo phosphorylation at
Tyr-705 or Ser-727, which is mediated by Janus kinase and Akt,
respectively (29), and that phospho-STAT3(Ser-727) has been
reported to regulate transcription activation inMAPK pathway
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as well (30), the effect of CIMO on phosphorylation of serine
727 in STAT3 was investigated next. Here it was found that
CIMO completely inhibited the phosphorylation of Tyr-705;
however, it had no effect on phosphorylation of Ser-727 (Fig. 2,
C and D), indicating that CIMO inhibits upstream tyrosine
kinases.
CIMO Depletes Nuclear Localization of STAT3 in HCC
Cells—Inhibition of phosphorylation of STAT3 at Tyr-705 sup-
presses nuclear translocation and down-regulates the expres-
sion of target genes (31). We hence evaluated whether CIMO
can inhibit nuclear translocation of STAT3. Fig. 2E clearly dem-
onstrates that CIMO causes a significant decrease of STAT3 in
the nucleus of HepG2 cells. This overall represents conclusive
evidence that CIMO inhibits phosphorylation of STAT3 and
accumulates in the cytoplasm.
CIMO Suppresses Constitutive Activation of c-Src, JAK1, and
JAK2 in HCC Cells—Given that the activation of STAT3 is reg-
ulated by soluble tyrosine kinases of c-Src and JAK family pro-
teins (32, 33). CIMO treatment presented significant inhibition
of phosphorylation of c-Src kinase, JAK1, and JAK2 (Fig. 2F),
without affecting the levels of c-Src, JAK1, and JAK2 proteins.
Therefore, the results obtained confirmed that inhibition of
STAT3 is due to the inhibition of c-Src and JAK family proteins.
CIMO Inhibits STAT3 DNA Binding Activity in HCC Cells—
We further investigated whether CIMO modulates STAT3
DNA binding activity in HepG2 cells because STAT3 dimer
translocates into the nucleus and binds to specific DNA nucle-
otide sequence to regulate gene expression (34, 35). CIMO sup-
pressed the binding of STAT3 to the DNA in a time-dependent
manner in HepG2 cells (Fig. 2G).
CIMO Inhibits STAT3-mediated Transcription Activity in
HepG2 Cells—Increased STAT3 activity has been previously
reported to stimulate oncogenicity of hepatocellular carcinoma
(14, 36). Therefore, we first evaluated the level of phosphory-
lated STAT3(Tyr-705) in HepG2 cells with siRNA-mediated
deletion of STAT3 transcripts and/or exposure to CIMO, using
Western blot analysis. Transient transfection of STAT3-di-
rected siRNA in HepG2 cells resulted in decreased levels of
phosho-STAT3 and total STAT3 protein compared with their
vector control cells, demonstrated using Western blot. On the
other hand, application of CIMO to HepG2 cells resulted in
decreased phospho-STAT3 levels compared with their control
cells exposed with DMSO (Fig. 3A). In contrast, the protein
levels of total STAT3 were not significantly altered in HepG2
cells upon exposure to CIMO, when compared with their
DMSO-exposed control.
In addition, we subsequently assessed STAT3-mediated
transcriptional activity using an 2-macroglobulin (2-M) pro-
moter in HepG2 cells with either siRNA-mediated depletion of
STAT3 expression or by exposure to CIMO (Fig. 3B). The
2-M reporter construct contains a fragment of the 2-M gene
promoter (215 to8 bp) to which STAT3 binds and induces
transcription of this gene. siRNA-mediated depletion of
STAT3 expression in HepG2 cells exhibited decreased 2-M
promoter activity when compared with their vector control
cells. Similarly, upon exposure to theCIMOcompound,HepG2
cells exhibited decreased 2-M promoter activity when com-
pared with their control cells exposed with DMSO.
CIMODown-regulates IL-6-induced JAK1, JAK2, and STAT3
Phosphorylation in HCC Cells—Elevated levels of serum IL-6
have been reported in various types of cancers, leading to the
overactivation of STAT3 (37, 38). Hep3B are HCC cells that
lack constitutively active JAK and STAT3 proteins. CIMO sub-
stantially down-regulated the IL-6-induced phosphorylation of
JAK1, JAK2, and STAT3 in Hep3B cells (Fig. 3C). These results
clearly demonstrate that CIMO modulates both constitutive
and inducible activation of proteins of the JAK-STAT pathway.
CIMO Regulates the Expression of STAT3-targeted Genes
Involved in Cell Proliferation and Survival—STAT3 activation
has been reported to regulate the expression of proapoptotic
and antiapoptotic proteins (39, 40). Therefore, we investigated
whether CIMO modulates the expression of various STAT3-
regulated proapoptotic and antiapoptotic genes. We found the
down-regulation of antiapoptotic proteins, including Bcl-2,
Bcl-xL, Survivin, ICAM-1, Bid, and cell cycle regulator cyclin
D1. We also found the up-regulation of proapoptotic protein
Bak in a time-dependentmannerwithmaximumactivity at 36 h
(Fig. 3, D and E). This finding provides evidence that CIMO
FIGURE 1. A, azaspirane scaffold (highlightedwith red circle) evolution. 1, atip-
rimod; 2, staurosporine; 3, lestaurtinib; 4, (2-(2,6-difluorophenyl)-5-(4-me-
thoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane) (DMBO). B, CIMO causes the
accumulation of HepG2 cells in the sub-G1 phase. HepG2 cells (5  10
5/ml)
were treatedwith 10mol/liter CIMO for the indicated times, after which the
cells were washed, fixed, stained with propidium iodide, and analyzed for
DNA content by flow cytometry.
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inhibits survival signaling on multiple levels, hence rendering
the cell more prone to apoptosis induction.
CIMOActivates Procaspase-3 and Induces Cleavage of PARP—
Activated caspase-3 cleaves the full-length PARP (116 kDa)
into 85- and 24-kDa fragments, and PARP is involved in the
DNA repair mechanism and drives the cell to apoptosis (41).
We investigated whether suppression of constitutively active
STAT3 by CIMO leads to apoptosis. Fig. 4A demonstrates the
activation of procaspase-3 and subsequent decline of full-
length PARP with an increase in the cleaved 85-kDa fragment
in a time-dependentmanner. These results clearly indicate that
CIMO induces caspase-3-mediated apoptosis in HepG2 cells.
FIGURE 2. A, CIMO suppresses phospho-STAT3 in a dose-dependent manner. HepG2 cells (5 105/ml) were treated with the indicated concentrations
of CIMO for 6 h, after which whole-cell extract was prepared and resolved on SDS-polyacrylamide gel, electrotransferred onto nitrocellulosemembrane,
and probed for phospho-STAT3, and the same blot was stripped and reprobedwith STAT3 antibody to verify equal protein loading. B, AG490 suppresses
phospho-STAT3 in a dose-dependent manner. HepG2 cells (5  105/ml) were treated with the indicated concentrations of AG490 for 6 h, after which
Western blotting was done as described for A. C, CIMO suppresses phospho-STAT3 levels in a time-dependent manner. HepG2 cells (5 105/ml) were
treated with 10 mol/liter CIMO for the indicated times, after which Western blotting was done as described for A. D, CIMO had no effect on phospho-
STAT3(Ser-727) and STAT3 protein expression. HepG2 cells (5  105/ml) were treated with 10 mol/liter CIMO for the indicated times, after which
Western blotting was done as described for A, and the membrane was probed using antibodies against phospho-STAT3(Ser-727) and STAT3. E, CIMO
inhibits the translocation of STAT3 to the nucleus. HepG2 cells (1 105/ml) were incubatedwith or without 10mol/liter CIMO for 6 h and then analyzed
for the intracellular distribution of STAT3 by immunocytochemistry. The same slides were counterstained for nuclei with Hoechst (50 ng/ml) for 5 min
and analyzed under a fluorescence microscope. F, CIMO suppresses phospho-Src, phospho-JAK1, and phospho-JAK2 levels in a time-dependent
manner. HepG2 cells (5  105/ml) were treated with 10 mol/liter CIMO, after which whole-cell extracts were prepared, resolved in SDS-PAGE,
electrotransferred onto nitrocellulose membranes, and probed with phospho-Src, phospho-JAK1, and phospho-JAK2 antibodies. The same blots were
stripped and reprobedwith Src, JAK1, and JAK2 antibodies to verify equal protein loading.G, CIMO suppresses STAT3 DNA binding ability in HepG2 cells.
HepG2 cells were treated with 10 mol/liter CIMO for the indicated time, nuclear extracts were prepared, and 5 g of the nuclear extract protein was
used for the ELISA-based DNA-binding assay. *, p  0.05.
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Tyrosine Phosphatases Are Involved in CIMO-induced Inhi-
bition of STAT3 Activation—Protein-tyrosine phosphatases
have been implicated in STAT3 activation (42).We determined
whether CIMO-induced inhibition of STAT3 tyrosine phos-
phorylation could be due to activation of a protein-tyrosine
phosphatase. Treatment of HepG2 cells with the broad spec-
trum tyrosine phosphatase inhibitor sodium pervanadate pre-
vented CIMO-induced inhibition of STAT3 activation (Fig.
4B). This suggests that tyrosine phosphatases are involved in
CIMO-induced inhibition of STAT3 activation. Based on
this, we also analyzed the expression of various tyrosine
phosphatases, including SHP-1, SHPTP-2, and PTP1B, upon
treatment with CIMO for up to 4 h and found no change in
the levels of these phosphatases (Fig. 4C). Based on these
results, we are hypothesizing the involvement of some other
phosphatases in the reversal of the effect of CIMO on STAT3
phosphorylation.
CIMO Suppresses CXCL12-induced HepG2 Cell Migration
and Invasion—STAT3-targeted gene products are known to be
involved in cancer cell migration (10). Fig. 5A interprets the
movement of the cells in the presence and absence of CIMO
and CXCL12. CIMO limits the HepG2 cell migration by nearly
50%, both in the presence and absence of CXCL12, compared
with the respective controls. In the case of the invasion assay,
more than 50% of HepG2 cell motility was inhibited both in the
presence and absence of CXCL12 across the polyethylene
terephthalatemembrane, suggesting thatCIMO interfereswith
cell invasion (Fig. 5B).
FIGURE 3. A, comparative study of cell viability between STAT3-siRNA-transfected and CIMO-treated HepG2 cells. Correspondingly, Western blot analysis was
used to assess the levels of phospho-STAT3 and STAT3 in HepG2 cells with siRNA-mediated depletion of STAT3 expression and upon exposure to 4M CIMO.
Whole-cell extract was prepared and resolved on SDS-polyacrylamide gel, electrotransferred onto nitrocellulosemembrane, and probed for phospho-STAT3,
and the same blot was stripped and reprobedwith STAT3 antibody and-actin to verify equal protein loading. B, CIMOmodulates STAT3-mediated transcrip-
tion and2-Mpromoter activity inHepG2 cells.C, CIMO inhibits IL-6-inducedphosphorylation of STAT3, JAK1, and JAK2. Hep3B cells (5 105/ml)were treated
with 10 mol/liter CIMO for the indicated times and then stimulated with IL-6 (10 ng/ml) for 15 min. Whole-cell extracts were then prepared, resolved on an
SDS-polyacrylamide gel, electrotransferred onto nitrocellulose membrane, and probed with phospho-STAT3, phospho-JAK1, and phospho-JAK2 antibodies.
The same blot was stripped and reprobed with STAT3, JAK1, and JAK2 antibody to verify equal protein loading. D and E, CIMO suppresses STAT3-regulated
gene products involved in cell proliferation and survival. HepG2 cells (5 105/ml) were treated with the 10 mol/liter CIMO for the indicated time intervals,
afterwhichwhole-cell extractwasprepared, resolvedonanSDS-polyacrylamidegel, andelectrotransferredontonitrocellulosemembrane, and themembrane
was sliced according tomolecular weight and probed against Bcl-2, cyclin D1, Survivin, Bak, ICAM-1, Bcl-xL, and Bid. The same blot was stripped and reprobed
with -actin antibody to verify equal protein loading. Error bars, S.E.
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CIMO Suppresses the Growth of Human HCC in Vivo and
STAT3 Activation in Tumor Tissues—We also tested the antitu-
mor potential of CIMO in vivo via intraperitoneal administration
in an orthotopic model of human HCC using Huh 7-Luc-trans-
fected cells. It was found that CIMO at a concentration of 10
mg/kg induced significant inhibition of tumor growth compared
with the DMSO-treated controls (Fig. 6A). The unpaired t test
showed a statistically significant difference in tumor growth
between the CIMO-treated and control groups (p value	 0.0385
as compared with the DMSO-treated control group). We further
analyzed the effect of CIMOon constitutive phospho-STAT3 lev-
els in HCC tumor tissues by immunohistochemical analysis and
found that CIMO significantly inhibited constitutive STAT3 acti-
vation in the treated versus control group (Fig. 6B). The effect of
CIMOwas also analyzed upon the expression of Ki-67 (marker of
proliferation) and cleaved caspase-3 (marker of apoptosis). As
shown in Fig. 7, expression of Ki-67was down-regulated, and that
of cleaved caspase-3 was significantly increased in the CIMO-
treated group, compared with control.
In Silico Interaction of CIMO with the Kinase Domain of
JAK2—In order to better understand compound action on a
mechanistic level, we also performed computational studies in
the next step. In the current study, CIMO showed potent anti-
cancer activity via the JAK2-STAT3 pathway; hence, we con-
sidered the possibility that CIMO interacts with the kinase
domain of JAK2 directly. Thus, the JAK2 inhibitor 1-methyl-
1H-imidazole, which modulated the JAK/STAT pathway, was
considered for our studies (20). Amolecular docking study was
carried out to examine the possibility of CIMO binding to the
kinase domain of JAK2. The docking scores of the biologically
active ligands with the kinase domain of JAK2 (Protein Data
Bank entry 4C61) are summarized (Fig. 8A) (20). Based on
Ligand Fit docking score calculations, CIMO shows a docking
score of 95.07 kcal/mol, which is higher when compared with
other structurally related azaspiranes. The known STAT3
inhibitors, such as Stattic and staurosporine, bound to the
kinase domain of JAK2 with predicted binding energies of 37.2
and 83.2 kcal/mol, respectively, which was comparable with
CIMO. Fig. 8 shows the best dockedpose ofCIMOas defined by
FIGURE 4. A, CIMO activates caspase-3 and induces apoptosis. HepG2 cells
(5  105/ml) were treated with 10 mol/liter CIMO for the indicated times,
and whole-cell extracts were prepared, separated on SDS-PAGE, and sub-
jected to Western blotting against caspase-3 and PARP antibody. The same
blot was stripped and reprobed with -actin antibody to show equal protein
loading. B, pervanadate reversed the inhibitory effect of CIMO on phospho-
STAT3. HepG2 cells (5 105/ml) were treated with the indicated concentra-
tions of pervanadate and 10 mol/liter CIMO for 4 h, after which whole-cell
extractswere prepared, resolved on an SDS-polyacrylamide gel, electrotrans-
ferred onto nitrocellulose membrane, and probed for phospho-STAT3 and
STAT3. C, inhibitory activity of CIMO on phospho-STAT3 is mediated by pro-
tein-tyrosine phosphatase. HepG2 cells (5  105/ml) were treated with 10
mol/liter CIMO for the indicated times; whole-cell extracts were prepared,
separated on SDS-PAGE, and subjected to Western blotting against PTP1B,
SHPTP1, and SHPTP2 antibody; and the sameblotwas stripped and reprobed
with -actin antibody to show equal protein loading.
FIGURE 5. A, CIMO inhibits cell migration. 70 l of HepG2 cells (5  105/ml)
were seeded into each compartment of the culture insert, and the insert was
removed after 12 h. The width of the woundwasmeasured initially, and cells
were incubated with and without CIMO (5 M, 8 h) and CXCL12 (100 ng/ml,
24 h). B, CIMO inhibits the cell invasion. HepG2 (2 105) cells were seeded in
the top chamber of BD BioCoatTM MatrigelTM. After preincubation with or
without 5 mol/liter CIMO for 8 h, transwell chambers were placed into the
wells of a 24-well plate that contained either only basal medium or basal
mediumwithCXCL12 (100ng/ml) for 24h. After incubation, the chamberwas
assessed for cell invasion by staining with crystal violet. Error bars, S.E.
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the highest DOCK score. The protein-ligand interactions as
shown in Fig. 8C have been classified into four clusters in order
to enable identification and comparison of interaction patterns
of CIMO moieties with specific JAK2 residues across other
known JAK2 inhibitors. In cluster 1, the cyano-biphenylmoiety
of CIMO bound to the hydrophobic pocket comprising Leu-
855, Gly-856, Ala-880, Met-929, Val-863, Leu-932, and Gly-
935. In cluster II, the indole moiety interacted with Gly-993,
Asp-994, Gly-882, and Ser-862. In cluster III, the cyclohexyl-
attached azaspirane moiety of CIMO bound to Gly-996, Leu-
997, Glu-898, Phe-895, Gly-861, and Leu-884. In addition, the
methoxy phenylmoiety of CIMO interactedwithAsp-894,His-
891, and Glu-890. These results indicate that CIMO could bind
strongly to the kinase domain of JAK2.
Cheminformatics-based Mode-of-action Rationalization for
CIMO Predicts the JAK-STAT Pathway as a Possible Target—
Rationalizing mode-of-action hypotheses utilizing the wealth
of experimental data available in the public domain is now pos-
sible with chemogenomics and cheminformatics applications
(43). In this regard, we applied the well established Laplacian-
modified naive Bayesian classifier as implemented by Koutsou-
kas et al. (44) and predicted potential targets of CIMO. It was
found that membrane-associated phospholipase A2, histamine
H2 receptor, proteinase-activated receptor 1, steroid hormone
receptor ERR1, gonadotrophin-releasing hormone receptor,
and prostaglandin E synthase had a normalized likelihood of
10.41, 4.98, 4.96, 4.43, 4.04, and 4.04 for CIMO, respectively.
These predicted targets for CIMO are known to cross-talk with
the JAK-STAT pathway (45). Therefore, the in silico rational-
ization of the mode-of-action analysis for CIMO suggested the
involvement of its anti-cancer effect through the JAK-STAT
pathway.
DISCUSSION
STAT3 is an inducible monomeric transcription factor that
dimerizes upon phosphorylation at Tyr-705 and translocates to
the nucleus. It relays the oncogenic signals by permitting the
expression of the target genes involved in uncontrolled cell pro-
liferation, angiogenesis, apoptotic resistance, and tumor eva-
sion. Therefore, inhibition of STAT3 signaling is an attractive
approach in order to inhibit cell proliferation. The aim of this
study was to synthesize new azaspirane-based small molecules
and to evaluate whether new compounds can disrupt STAT3
signaling. This work reported the synthesis of 13 new azaspi-
rane derivatives, which resulted in the discovery of CIMO as a
lead molecule that exhibited good cytotoxic effect on HCC
cells. CIMO inhibits constitutive and IL-6-induced activation
of STAT3, and its inhibitory effect is specific toTyr-705 inHCC
cells. The role of STAT3 phosphorylation at Tyr-705 in tumor-
FIGURE 6. CIMO inhibits the growth of human HCC in vivo. A, representa-
tive images ofmice frombioluminescent imaging.B, relative tumorburden in
athymic mice bearing orthotopically implanted Huh 7-Luc2 tumors treated
with vehicles alone (n 	 5) or 2 mg/kg (n 	 6) or 10 mg/kg (n 	 6) CIMO.
Points, mean; bars, S.E. *, p 0.05 (unpaired Student’s t test).
FIGURE 7. Immunohistochemical analysis of phospho-STAT3 (p-STAT3),
Ki-67, and caspase-3 showed the inhibition in expression of phospho-
STAT3,andKi-67and increased levelsof cleavedcaspase-3expression in
CIMO-treated samples as comparedwith the control group. The percent-
age indicates positive staining for the given biomarker. The photographs
were taken at a magnification of40.
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igenesis is well established; on the other hand, STAT3 can
undergo phosphorylation at Ser-727, and its role in cancer pro-
gression remains controversial (46, 47). Moreover, CIMO
proved to be a more effective inhibitor of the JAK-STAT path-
way than AG490. Our results indicate that CIMO specifically
inhibits Tyr-705 phosphorylation while showing no effect on
Ser-727 phosphorylation in HCC cells. An inhibitory effect of
CIMO on STAT3 phosphorylation was evident with the down-
regulation of JAK1, JAK2, and c-Src proteins. JAK and c-Src
proteins are the foremost tyrosine kinases with a critical role in
STAT3 phosphorylation (48). This result confirms the CIMO-
mediated blockade of upstreamprotein-tyrosine kinases in reg-
ulating aberrant behavior of STAT3 in the cancer cells.
Restriction of nuclear translocation and accumulation of
STAT3 in the cytoplasm is a hallmark of abrogation of the JAK-
STAT pathway. After understanding the critical role of phos-
pho-STAT3 as a latent transcription factor, we analyzed the
distribution of STAT3 in CIMO-treated HepG2 cells. The
results obtained provide strong evidence demonstrating
the link between phosphorylation and shuttling of STAT3 into
the nucleus. A reduction in nuclear localization of STAT3
directly correlated with the decreased phosphorylation of
STAT3 in the previous experiment. Gritsko et al. (49) have
reported that STAT3 induces survivin gene expression and
leads to apoptotic resistance. We also found that down-regula-
tion of STAT3 regulated tumorigenic proteins, including Bcl-2,
FIGURE 8. Bioinformatics approach of CIMO interaction toward the kinase domain of JAK2. A, ribbon diagram of themonomer of the JAK2 and its ligand
binding site (LBS) of kinase domain (green). B, surface view of JAK2 and the bound CIMO in the ligand binding site region. C, interactionmap of ligand binding
site domain of JAK2 that interacted with CIMO. The labeled key amino acids are represented as a line modelwith the carbon atom in black, and other atoms in
their parent colors. Shown is the binding of CIMO, whose carbon atom is green, and other atoms with their parent colors.
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Bcl-xL, cyclin D1, survivin, ICAM-1, and Bid. This suggests the
role of CIMO in limiting the expression of IAP (inhibitor of
apoptosis) and cell cycle-regulating proteins. In addition, PARP
and CAD (caspase-activated DNase) are two well known sub-
strates of caspase-3. Activated caspase-3 catalyzes activation of
CAD and cleavage of PARP, which results in formation of DNA
oligomers. Our results on the cleavage of procaspase-3 and
PARP and the deposition of hypodiploid cells in sub-G1 phase
markedly indicated the apoptosis-inducing effect of CIMO in
HCC cells.
SHP1, SH-PTP2, PTP-1B, and PTEN are some of the impor-
tant protein-tyrosine phosphatases connected with STAT3 sig-
naling. We further investigated the involvement of protein-ty-
rosine phosphatases in the suppression of STAT3 activation.
Treatment of sodium pervanadate reversed the effect of CIMO
on inhibition of STAT3 activation. This observation suggests
the involvement of phosphatases in CIMO-induced STAT3
inhibition. Our experiments suggested that SHP1, SHPTP2,
and PTP1B are not involved in the reversal of CIMO-induced
STAT3 inhibition, but it is not clear which specific phosphatase
is involved in this process, and it requires further investigation.
We also demonstrated the substantial decline in HCC develop-
ment in an orthotopicmousemodel. This observation was sup-
ported by immunohistochemistry analysis data in which Ki-67
(biomarker of proliferation) and phospho-STAT3 levels were
significantly down-regulated with a simultaneous increase in
cleaved caspase-3 (biomarker of apoptosis) in tumor tissues
treated with CIMO.Our results overall demonstrate the CIMO
is a potent agent with an antiproliferative effect in vitro and in
vivo, which shows its effect on HCC via abrogation of the JAK-
STAT signaling cascade.
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